Enhancement of radiosensitivity by a unique novel NF-B inhibitor, DHMEQ, in prostate cancer

British Journal of Cancer

Volumn 107, Issue 4, 2012, Pages 652-657

  Kozakai, N ^a   Kikuchi, E ^a   Hasegawa, M ^a   Suzuki, E ^b   Ide, H ^a   Miyajima, A ^a   Horiguchi, Y ^c   Nakashima, J ^c   Umezawa, K ^b   Shigematsu, N ^a   Oya, M ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

nuclear factor B; prostate cancer; radiation

Indexed keywords

DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P21; PROTEIN P53; STRATIFIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SIZE; CELL CYCLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOHEXANONES; HUMANS; MALE; MICE; MICE, NUDE; NF-KAPPA B; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864882225     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.321     Document Type: Article

References (31)

1. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K (2002) Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 277: 24625-24630
2. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D (1991) Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest 88: 691-695
3. Chen X, Shen B, Xia L, Khaletzkiy A, Chu D, Wong JY, Li JJ (2002) Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res 62: 1213-1221
4. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM (2004) Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23: 1599-1607
5. Chin C, Bae JH, Kim MJ, Hwang JY, Kim SJ, Yoon MS, Lee MK, Kim DW, Chung BS, Kang CD, Kim SH (2005) Radiosensitization by targeting radioresistance- related genes with protein kinase A inhibitor in radioresistant cancer cells. Exp Mol Med 37: 608-618
6. Davis JN, Kucuk O, Sarkar FH (1999) Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 35: 167-174
7. Dellinger RW, Karjian PL, Neuteboom ST (2003) NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint. Anticancer Drugs 14: 449-455
8. Flynn Jr. V, Ramanitharan A, Moparty K, Davis R, Sikka S, Agrawal KC, Abdel-Mageed AB (2003) Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells. Int J Oncol 23: 317-323
9. Han B, Xie H, Chen Q, Zhang JT (2006) Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma. Mol Cancer Ther 5: 903-912
10. Hanks GE, Hanlon AL, Epstein B, Horwitz EM (2002) Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54: 427-435
11. Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K, Murai M (2003) Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res 63: 107-110
12. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA (2004) Radical prostatectomy, external beam radiotherapy o72 Gy, external beam radiotherapy 4or 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58: 25-33
13. Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, Murai M (2005) Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer. Clin Cancer Res 11: 5590-5594
14. Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K (2005) Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res 11: 1287-1293
15. Matsumoto N, Ariga A, To-e S, Nakamura H, Agata N, Hirano S, Inoue J, Umezawa K (2000) Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 10: 865-869
16. Ohsugi T, Horie R, Kumasaka T, Ishida A, Ishida T, Yamaguchi K, Watanabe T, Umezawa K, Urano T (2005) In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 26: 1382-1388
17. Pajonk F, Pajonk K, McBride WH (1999) Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst 91: 1956-1960
18. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD (1999) Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18: 7389-7394
19. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53: 1097-1105
20. Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG (2006) Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6: 107
21. Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S (2004) Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res 10: 6821-6829
22. Sun St Y, Clair DK, Fang F, Warren GW, Rangnekar VM, Crooks St PA, Clair WH (2007) The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther 6: 2477-2486
23. Takagi M, Delia D, Chessa L, Iwata S, Shigeta T, Kanke Y, Goi K, Asada M, Eguchi M, Kodama C, Mizutani S (1998) Defective control of apoptosis, radiosensitivity, and spindle checkpoint in ataxia telangiectasia. Cancer Res 58: 4923-4929
24. Takatsuna H, Umezawa K (2004) Screening of bioactive metabolites for pancreatic regeneration chemotherapy. Biomed Pharmacother 58: 610-613
25. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, Lin A (2001) Inhibition of JNK activation through NF-kappaB target genes. Nature 414: 313-317
26. Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815
27. Vousden KH (2002) Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 1602: 47-59
28. Watanabe M, Dewan MZ, Okamura T, Sasaki M, Itoh K, Higashihara M, Mizoguchi H, Honda M, Sata T, Watanabe T, Yamamoto N, Umezawa K, Horie R (2005) A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 114: 32-38
29. Wen B, Deutsch E, Eschwege P, De Crevoisier R, Nasr E, Eschwege F, Bourhis J (2003) Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells. J Urol 170: 2036-2039
30. Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K (2008) Inactivation of NF-kappaB components by covalent binding of (-)- dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 51: 5780-5788
31. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166: 876-881